Back
SpartanNash 10K Form
Sell
46
SPTN
SpartanNash
Last Price:
$18.49
Seasonality Move:
9.06%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-30 | 10Q | SPTN/SpartanNash Quarterly |
2023-11-09 | 10Q | SPTN/SpartanNash Quarterly |
2023-08-17 | 10Q | SPTN/SpartanNash Quarterly |
2023-06-01 | 10Q | SPTN/SpartanNash Quarterly |
2022-11-10 | 10Q | SPTN/SpartanNash Quarterly |
2022-08-18 | 10Q | SPTN/SpartanNash Quarterly |
Receive SPTN News And Ratings
See the #1 stock for the next 7 days that we like better than SPTN
SPTN Financial Statistics
Sales & Book Value
Annual Sales: | $9.7B |
---|---|
Cash Flow: | $-39.6M |
Price / Cash Flow: | 16.38 |
Annual Sales: | $23.15 |
Price / Book: | 0.8 |
Profitability
EPS (TTM): | 1.33000 |
---|---|
Net Income (TTM): | $45.7M |
Gross Margin: | $1.5B |
Return on Equity: | 5.86% |
Return on Assets: | 1.92% |
SpartanNash Earnings Forecast
Key SpartanNash Financial Ratios
-
The Gross Profit Margin over the past 27 years for SPTN is 15.27%.
-
The Selling, General & Administrative Expenses for SPTN have been equal to 14.04% of Gross Profit Margin.
-
The Research & Development expenses have been 0.00% of Revenue.
-
The Interest Expense is 76.36% of Operating Income.
-
The Net Earning history of SPTN is 0.54% of Total Revenues.
-
Per Share Earnings over the last 27 years have been positive in 14 years.
SpartanNash Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Consumer Staples Distribution & Retail |
Sector: | Consumer Staples |
Current Symbol: | SPTN |
CUSIP: | 847215 |
Website: | spartannash.com |
Debt
Debt-to-Equity Ratio: | 0.81 |
---|---|
Current Ratio: | 1.62 |
Quick Ratio: | 0.72 |
Price-to-Earnings
Trailing P/E Ratio: | 12.35 |
---|---|
Forward P/E Ratio: | 9.49 |
SPTN Technical Analysis vs Fundamental Analysis
Sell
46
SpartanNash (SPTN)
is a Sell
Is SpartanNash a Buy or a Sell?
-
SpartanNash stock is rated a SellThe current SpartanNash [SPTN] share price is $18.52. The Score for SPTN is 46, which is 8% below its historic median score of 50, and infers higher risk than normal.